

## ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Please complete the ABSTRACT TEMPLATE online, for Biomed 2025 Company Presentations  
All items marked with an \* are mandatory to complete  
The maximum number of words for this abstract is 400  
Please be sure to complete the following:

Company name NeuroSense Therapeutics Ltd. \* Website <https://www.neurosense-tx.com/> \*

CEO name Alon Ben-Noon \*

Select a CATEGORY: Biotech \*  
(Delete categories you are not selecting)

Select up to two SESSIONS per abstract from the list below \*  
(Delete sessions you are not selecting)

- Rewiring the Brain; Breakthroughs in Neurotech and Neuromodulation

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) is a clinical-stage biotechnology company dedicated to developing innovative treatments for neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease.

The company's lead drug candidate, PrimeC, is a proprietary oral formulation that uniquely combines two FDA-approved compounds at optimized doses to synergistically target multiple key disease pathways. PrimeC is designed to modulate neuroinflammation, iron accumulation, and RNA-binding protein dysfunction, all of which are central to ALS progression.

In a recent Phase 2b clinical trial, PrimeC demonstrated promising safety, efficacy, and biomarker data, and is now advancing toward a pivotal Phase 3 trial.

Driven by a mission to bring hope and time to patients with no cure, NeuroSense is committed to rigorous science, compassionate development, and collaboration with global partners to accelerate impact.